UBS Maintains Buy on Merck & Co, Lowers Price Target to $136
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Buy rating on Merck & Co (NYSE:MRK) but lowers the price target from $142 to $136.
October 09, 2024 | 10:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst Colin Bristow maintains a Buy rating on Merck & Co but lowers the price target from $142 to $136, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in Merck's performance, but the lowered price target indicates a slightly less optimistic view on its short-term potential. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100